본문 바로가기 주메뉴 바로가기

News & Media

Press Releases


Executive Summary

Admin 2026-10-06 00:00:00 Views 9,311

Executive Summary

We took an effective chemotherapy drug and made it much safer, with no side effects.

Onselex Pharmaceuticals has developed ONX-1006, a nanoparticle-based cancer treatment designed to concentrate paclitaxel (PTX), a proven chemotherapy drug, in tumors while protecting normal cells.

1. Outstanding Results and Development Goals

  • Continuous Treatment: One year or longer of continuous ONX-1006 (PTX) chemotherapy treatment.
  • Without Side Effects: Continuous chemotherapy treatment without side effects, enabling ongoing tumor cell death.
  • Outstanding Antitumor Efficacy: 20% greater tumor reduction than Abraxane at the same weekly PTX dose in a pancreatic cancer animal test.
  • Tumor Elimination Goal: 90–100%.
  • Stage IV Pancreatic Cancer One-Year Survival Goal: 70%.

Treatment duration, tumor elimination, and survival figures are future clinical development goals based on preclinical results.

2. Supporting Safety Data

  • Over 30 preclinical studies and about 4,000 pages of supporting data.
  • Strong safety findings in repeat-dose GLP toxicity studies involving rats and beagle dogs.
  • Beagle dogs, once weekly for 4 weeks: No Side Effects at a dose equivalent to about 480 mg PTX for a 60 kg adult.
  • Female beagle dogs, once weekly for 13 weeks: No Side Effects at a dose equivalent to about 320 mg PTX for a 60 kg adult.
  • 2.4 and 1.6 times a typical 200 mg Abraxane (PTX) dose. Severe side effects from Abraxane may require dose reductions or treatment discontinuation.

3. Supporting Antitumor Efficacy Data

  • Highest level of cancer cell death in the comparative preclinical study.
  • Prolonged blood circulation and higher PTX concentrations within tumors.
  • Uses established chemotherapy anticancer activity.

4. FDA IND Package and SEND Completion

  • November 6, 2026: Completed the FDA IND application package for ONX-1006.
  • 15 SEND-applicable studies and 199 electronic datasets: All successfully passed Pinnacle 21 validation, a tool used by the U.S. FDA.
  • Estimated U.S. Development Cost: $1 million or more to complete an FDA IND application package and SEND datasets of this scope.
  • Estimated Development Time: 6–9 months of specialized regulatory preparation.
  • Remaining Major Step: cGMP clinical manufacturing batch. Onselex is raising capital to fund this batch and the first human trial.

The IND has not yet been submitted. FDA submission will follow completion of the cGMP clinical batch.

5. Manufacturing Readiness

  • Standardized ONX-1006 manufacturing process.
  • 15 kg of nanoparticles successfully produced.

6. Pancreatic Cancer Market Benchmark

RASONQUE (Daraxonrasib) – Revolution Medicines (RVMD)

  • FDA Approval: Metastatic pancreatic cancer in eligible adults, August 2026.
  • One Drug, $45 Billion: Market cap, October 2026.
  • Survival Benefit: ~6.5 months longer vs. chemotherapy.
  • One-Year Survival Rate: 53.2%.
  • Grade ≥3 Treatment-Related Adverse Events: 43.6%.

7. Near-Term Clinical Development

  • Development Roadmap: cGMP clinical manufacturing → U.S. FDA IND filing → South Korea MFDS clinical trial approval → First clinical trial in South Korea (Cohort 1).
  • Initial Cohort: Eight treatment-naïve patients with Stage IV pancreatic cancer in the planned Phase I/IIa clinical trial.
  • U.S. FDA IND Integration: The South Korea clinical trial is planned to be included under the U.S. FDA IND, with clinical trial results to be submitted to the FDA.

For investment or strategic partnership opportunities, please visit our Investor & Partner page and submit the inquiry form.

Company Video: Watch Company Video

Contact: CureCancer@OnSelex.com

Executive Summary (PDF)

View the full Executive Summary below, or open it directly using the link.

View or Download Executive Summary (PDF)

If the PDF does not display in your browser, use the download link above.